84|8502|Public
50|$|SR-57227 is {{a potent}} and {{selective}} agonist at the 5HT3 receptor, with high selectivity over other serotonin receptor subtypes and good <b>blood-brain</b> <b>barrier</b> <b>penetration.</b>|$|E
50|$|CP-615,003 {{is a drug}} {{which acts}} as a subtype-selective partial agonist at GABAA receptors, and was {{developed}} by Pfizer as a potential anxiolytic; however, poor <b>blood-brain</b> <b>barrier</b> <b>penetration</b> make it primarily useful as a research ligand.|$|E
50|$|Because of its {{excellent}} <b>blood-brain</b> <b>barrier</b> <b>penetration</b> (far {{superior to}} any of the cephalosporins), chloramphenicol remains the first-choice treatment for staphylococcal brain abscesses. It is also useful in the treatment of brain abscesses due to mixed organisms or when the causative organism is not known.|$|E
30|$|The {{present study}} {{addresses}} the radiosynthesis and first preclinical {{evaluation of the}} novel NET PET tracer [11 C]Me@HAPTHI by describing its affinity, selectivity, metabolic stability, plasma free fraction, <b>blood–brain</b> <b>barrier</b> (BBB) <b>penetration</b> and binding behaviour in in vitro autoradiography.|$|R
30|$|We have {{explored}} {{the possibility that}} the serotonin 1 B receptor radioligand [11 C]AZ 10419369 is a substrate for adenosine triphosphate (ATP)-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), Mrp 4, and Bcrp, in rodents and whether there is a species difference regarding its <b>blood-brain</b> <b>barrier</b> (BBB) <b>penetration.</b>|$|R
30|$|Intradural metastases remain {{outside the}} <b>blood-brain</b> <b>barrier</b> which allows <b>penetration</b> of {{chemotherapy}} [28]. This is different to parenchymal and leptomeningeal deposits where the <b>blood-brain</b> <b>barrier</b> impedes its action. Outcomes are therefore relatively good for dural lesions, and the distinction {{should be made}} when imaging is used to plan therapy regimens.|$|R
5000|$|Traversal of the {{blood-brain barrier}} by C. neoformans {{plays a key}} role in {{meningitis}} pathogenesis. However, precise mechanisms by which it passes the blood-brain barrier are still unknown; one recent study in rats suggested an important role of secreted serine proteases. [...] The metalloprotease Mpr1 has been demonstrated to be critical in <b>blood-brain</b> <b>barrier</b> <b>penetration.</b>|$|E
50|$|CB-13 (CRA13, SAB-378) is a {{cannabinoid}} drug, {{which acts}} as a potent agonist at both the CB1 and CB2 receptors, but has poor <b>blood-brain</b> <b>barrier</b> <b>penetration,</b> and so produces only peripheral effects at low doses, with symptoms of central effects such as catalepsy only appearing at much higher dose ranges. It has antihyperalgesic properties in animal studies, and has progressed to preliminary human trials.|$|E
50|$|Conessine is a steroid {{alkaloid}} {{found in}} a number of plant species from the Apocynaceae family, including Holarrhena floribunda, Holarrhena antidysenterica and Funtumia elastica. It acts as a histamine antagonist, selective for the H3 subtype (with an affinity of pKi = 8.27; Ki = ~5 nM). It was also found to have long CNS clearance times, high <b>blood-brain</b> <b>barrier</b> <b>penetration</b> and high affinity for the adrenergic receptors.|$|E
30|$|The {{in vitro}} {{evaluation}} of Me@HAPTHI and its precursor HAPTHI. Evaluation includes binding studies for {{the determination of}} affinity and selectivity of both Me@HAPTHI and its precursor HAPTHI towards NET using NET, serotonin transporter (SERT) and dopamine transporter (DAT) expressing membranes, metabolic stability testing in vitro against Cytochrom P 450 enzymes, logP analysis and immobilized artificial membrane (IAM) chromatography for indirect measurement of the <b>blood–brain</b> <b>barrier</b> (BBB) <b>penetration</b> and determination of plasma free fraction.|$|R
40|$|The <b>blood–brain</b> <b>barrier</b> is a {{specialized}} protective {{structure in the}} central nervous system, which is critical for maintaining brain homeostasis and low permeability to control the passage of molecules from the circulation into the brain parenchyma and the efflux from the brain. However, the <b>blood–brain</b> <b>barrier</b> also hinders the transportation of therapeutic agents and contrast agents from the blood into brain tissue, lowering treatment efficiency. Recently, focused ultrasound sonication with microbubbles has been proved to transiently open the <b>blood–brain</b> <b>barrier,</b> allowing the <b>penetration</b> of administered agents or drugs into the brain. In this article, we review {{the current state of}} this drug delivery technique, its application in preclinical brain disease models, and treatment planning for this novel technique...|$|R
40|$|Several prodrug {{approaches}} {{were taken}} to mask amino groups in two potent and selective neuronal nitric oxide synthase (nNOS) inhibitors containing either a primary or secondary amino group to lower the charge and improve <b>blood-brain</b> <b>barrier</b> (BBB) <b>penetration.</b> The primary amine was masked as an azide and the secondary amine as an amide or carbamate. The azide was not reduced to the amine {{under a variety of}} in vitro and ex vivo conditions. Despite the decrease in charge of the amino group as an amide and as carbamates, BBB penetration did not increase. It appears that the use of azides as prodrugs for primary amines or amides and carbamates as prodrugs for secondary amines are not universally effective approaches for CNS applications. Keywords amine prodrug; neuronal nitric oxide synthase inhibitor; blood-brain barrier; organic azide 1...|$|R
50|$|PipISB {{is a drug}} used in {{scientific}} research which acts as a potent and selective inverse agonist of the cannabinoid receptor CB1. It is highly selective for the CB1 receptor over CB2, with a Kd at CB1 of 1.5nM vs over 7000nM at CB2, has good <b>blood-brain</b> <b>barrier</b> <b>penetration,</b> and can be conveniently radiolabelled with either 11C or 18F, making it useful for mapping the distribution of CB1 receptors in the brain.|$|E
50|$|Pralidoxime has an {{important}} role in reversing paralysis of the respiratory muscles but due to its poor <b>blood-brain</b> <b>barrier</b> <b>penetration,</b> it has little effect on centrally-mediated respiratory depression. Atropine, which is choice of drug to antagonise the muscarinic effects of organophosphates, is administered even before pralidoxime during the treatment of organophosphate poisoning. While the efficacy of atropine has been well-established, clinical experience with pralidoxime has led to widespread doubt about its efficacy in treatment of organophosphorus poisoning.|$|E
50|$|AZ-11713908 {{is a drug}} {{developed}} by AstraZeneca which is a peripherally selective cannabinoid agonist, acting as a potent agonist at the CB1 receptor and a partial agonist at CB2. It has poor <b>blood-brain</b> <b>barrier</b> <b>penetration,</b> and so while it is an effective analgesic in animal tests, it produces only peripheral effects at low doses, with much weaker symptoms of central effects compared to other cannabinoid drugs such as WIN 55,212-2. A large number of related benzimidazole derived cannabinoid ligands are known.|$|E
40|$|Ca 2 + blockers, {{particularly}} those capable of crossing the <b>blood-brain</b> <b>barrier</b> (BBB), {{have been suggested}} as a possible treatment or disease modifying agents for neurodegenerative disorders, e. g., Alzheimer's disease. The present study investigated {{the effects of a}} novel 4 -(N-dodecyl) pyridinium group-containing 1, 4 -dihydropyridine derivative (AP- 12) on cognition and synaptic protein expression in the brain. Treatment of AP- 12 was investigated in wild type C 57 BL/ 6 J mice and transgenic Alzheimer's disease model mice (Tg APPSweDI) using behavioral tests and immunohistochemistry, as well as mass spectrometry to assess the <b>blood-brain</b> <b>barrier</b> (BBB) <b>penetration.</b> The data demonstrated the ability of AP- 12 to cross the BBB, improve spatial learning and memory in both mice strains, induce anxiolytic action in transgenic mice, and increase expression of hippocampal and cortical proteins (GAD 67, Homer- 1) related to synaptic plasticity. The compound AP- 12 {{can be seen as a}} prototype molecule for use in the design of novel drugs useful to halt progression of clinical symptoms (more specifically, anxiety and decline in memory) of neurodegenerative diseases, particularly Alzheimer's disease...|$|R
40|$|E. coli is {{the most}} common Gram-negative {{bacteria}} causing neonatal meningitis, and E. coli meningitis continues to be an important cause of mortality and morbidity throughout the world. Recent reports of E. coli meningitis caused by antimicrobial resistant strains are a particular concern. These findings indicate that a novel strategy is needed to identify new targets for prevention and therapy of E. coli meningitis. Cytotoxic necrotizing factor 1 (CNF 1) is a bacterial virulence factor associated principally with E. coli strains causing urinary tract infection and meningitis. We have shown that CNF 1 contributes to E. coli invasion of the <b>blood-brain</b> <b>barrier</b> and <b>penetration</b> into the brain, the essential step in the development of E. coli meningitis, and identified the host receptor for CNF 1, 37 -kDa laminin receptor precursor (37 LRP). CNF 1, however, is a cytoplasmic protein and its contribution to E. coli invasion of the <b>blood-brain</b> <b>barrier</b> requires its secretion from the bacterial cytoplasm. No signal peptide is found in the CNF 1 sequence. CNF 1 secretion is, therefore, a strategy utilized by meningitis-causing E. coli to invade the <b>blood-brain</b> <b>barrier.</b> Elucidation of the mechanisms involved in CNF 1 secretion, as shown in this report with the involvement of Fdx and YgfZ provides the novel information on potential targets for prevention and therapy of E. coli meningitis by virtue of targeting the secretion of CNF 1...|$|R
40|$|International audienceIn {{an effort}} toward the {{visualization}} of β-amyloid plaques by in vivo imaging techniques, we have conjugated an optimized derivative of the Pittsburgh compound B (PiB), a well-established marker of Aβ plaques, to DO 3 A-monoamide that {{is capable of}} forming stable, noncharged complexes with different trivalent metal ions including Gd 3 + for MRI and 111 In 3 + for SPECT applications. Proton relaxivity measurements evidenced binding of Gd(DO 3 A-PiB) to the amyloid peptide Aβ 1 - 40 and to human serum albumin, resulting in a two- and four-fold relaxivity increase, respectively. Ex vivo immunohistochemical studies showed that the DO 3 A-PiB complexes selectively target Aβ plaques on Alzheimer's disease human brain tissue. Ex vivo biodistribution data obtained for the 111 In-analogue pointed to a moderate <b>blood-brain</b> <b>barrier</b> (BBB) <b>penetration</b> in adult male Swiss mice (without amyloid deposits) with 0. 36 % ID/g in the cortex at 2 min postinjection...|$|R
50|$|Treatment {{measures}} have been described. Treatment is typically with the antidotes, atropine and pralidoxime. Atropine, an antagonist to muscarinic acetylcholine receptors, is given to treat the physiological symptoms of poisoning. Since muscular response to acetylcholine is mediated through nicotinic acetylcholine receptors, atropine does not counteract the muscular symptoms. Pralidoxime can regenerate cholinesterases if administered within approximately five hours. Biperiden, a synthetic acetylcholine antagonist, has been suggested {{as an alternative to}} atropine due to its better <b>blood-brain</b> <b>barrier</b> <b>penetration</b> and higher efficacy.|$|E
5000|$|The {{compound}} {{is basically}} a conjugate between the well-known cytotoxic and mutagenic residue of N-nitroso-N-methylurea and the sugar L-arabinose. The L-arabinose is a well-known component of some other effective anticancer drug molecules, including cytarabine (cytosine arabinoside) and fludarabine (2-fluoro-arabinoside of the nucleoside adenosine). The presence of L-arabinoside residue in the molecule greatly improves its penetration into malignant cells and its <b>blood-brain</b> <b>barrier</b> <b>penetration</b> and, while maintaining or even increasing anticancer activity, reduces the toxicity for normally fast dividing cells (bone marrow cells and mucosa of the gastro-intestinal system), improving the concentration ratio [...] "tumor / normal tissue".|$|E
50|$|This {{explained}} the previous failures, as most alterations to the pregabalin molecule which increase {{affinity for the}} α2δ channels and therefore increase apparent potency in the test tube, were found to also dramatically reduce binding to the system L transporter, and with no assisted transport into the brain, <b>blood-brain</b> <b>barrier</b> <b>penetration</b> was minimal and the drugs were inactive in animals. However, after extensive searching {{it was discovered that}} one enantiomer of the relatively simple derivative 4-methylpregabalin, was both 4x higher in binding affinity to α2δ channels than pregabalin, and also retained similar affinity for the system L transporter. This was tested in animals and as hoped, was found to have similar effectiveness to pregabalin as an analgesic and with around 2-3x the potency.|$|E
40|$|Background: The {{norepinephrine}} transporter (NET) {{has been}} demonstrated to be relevant to a multitude of neurological, psychiatric and cardiovascular pathologies. Due to {{the wide range of}} possible applications for PET imaging of the NET together with the limitations of currently available radioligands, novel PET tracers for imaging of the cerebral NET with improved pharmacological and pharmacodynamic properties are needed. Methods: The present study addresses the radiosynthesis and first preclinical evaluation of the novel NET PET tracer [11 C]Me@HAPTHI by describing its affinity, selectivity, metabolic stability, plasma free fraction, <b>blood–brain</b> <b>barrier</b> (BBB) <b>penetration</b> and binding behaviour in in vitro autoradiography. Results: [11 C]Me@HAPTHI was prepared and displayed outstanding affinity and selectivity as well as excellent in vitro metabolic stability, and it is likely to penetrate the BBB. Moreover, selective NET binding in in vitro autoradiography was observed in human brain and rat heart tissue samples. Conclusions: All preclinical results and radiosynthetic key-parameters indicate that the novel benzothiadiazole dioxide-based PET tracer [11 C]Me@HAPTHI is a feasible and improved NET radioligand and might prospectively facilitate clinical NET imaging...|$|R
40|$|Group B Streptococcus (GBS) is {{the most}} common {{bacterium}} causing neonatal meningitis, and neonatal GBS meningitis continues to be an important cause of mortality and morbidity. Here we provide the first direct evidence that host cytosolic phospholipase A 2 (cPLA 2) contributes to type III GBS invasion of human brain microvascular endothelial cells (HBMEC), which constitute the <b>blood-brain</b> <b>barrier</b> and <b>penetration</b> into the brain, the key step required for the development of GBS meningitis. This was shown by our demonstration that pharmacological inhibition and gene deletion of cPLA 2 significantly decreased GBS invasion of the HBMEC monolayer and penetration into the brain. cPLA 2 releases arachidonic acid from membrane phospholipids, and we showed that the contribution of cPLA 2 to GBS invasion of HBMEC involved lipoxygenated metabolites of arachidonic acid, cysteinyl leukotrienes (LTs). In addition, type III GBS invasion of the HBMEC monolayer involves protein kinase C (PKC), as shown by time-dependent PKC activation in response to GBS as well as decreased GBS invasion in HBMEC expressing dominant-negative PKC. PKC activation in response to GBS, however, was abolished by inhibition of cPLA 2 and cysteinyl LTs, suggesting that cPLA 2 and cysteinyl LTs contribute to type III GBS invasion of the HBMEC monolayer via PKC. These findings demonstrate that specific host factors involving cPLA 2 and cysteinyl LTs contribute to type III GBS <b>penetration</b> of the <b>blood-brain</b> <b>barrier</b> and their contribution involves PKC...|$|R
40|$|We {{reported}} earlier on radiolabeled alkoxyphenyl bicyclic nucleoside analogues (BCNAs) as potential {{positron emission tomography}} (PET) reporter probes for imaging of varicella zoster virus thymidine kinase (VZV-tk) gene in vivo. Despite their favorable physicochemical properties, these tracers are not taken up in the brain in mice. In order to probe {{the role of the}} deoxyribose sugar moiety in <b>blood-brain</b> <b>barrier</b> (BBB) <b>penetration</b> of these molecules, we have synthesized and evaluated a carbon- 11 -labeled acyclic bicyclic nucleoside derivative ([C- 11]- 10) where the 2 '-deoxyribose sugar is replaced with a (2 -hydroxyethoxy) methyl group and [C- 11]- 12, which has no sugar moiety but a [C- 11]methyl group on the N- 3 position of the pyrimidine ring. Methylation was achieved on the phenol [C- 11]- 10) or the N- 3 position ([C- 11]- 12) using [C- 11]methyl triflate (radiosynthesis). The (non-radioactive) acyclic O-methyl derivative 10 has rather poor affinity for the enzyme VZV-TK in vitro (IC 50 : 430 mu M), compared with the moderate affinity of the BCNA-base N-methyl derivative 12 (IC 50 : 79 mu M). In normal mice, none of the two tracers ([C- 11]- 10 or [C- 11]- 12) showed significant uptake in the brain, suggesting that compounds containing a furo[2, 3 -d]pyrimidine system do not cross the BBB. status: publishe...|$|R
50|$|The {{relatively}} poor oral bioavailability and <b>blood-brain</b> <b>barrier</b> <b>penetration</b> of CX-717 {{ultimately led}} to Cortex abandoning development of the 800 mg oral formulation of CX-717 for ADHD, although research into its action in the brain continues. However the unexpected discovery of the strong respiratory stimulant effects of the ampakine drugs on the pre-Botzinger complex of the brain has led to continued development of an intravenous formulation of CX-717 for use alongside opioid analgesics, along with an oral formulation of CX-1739, which is around 3-5x more potent than CX-717 and has better oral bioavailability, and is being trialled for treatment of sleep apnoea. Further research has investigated the neurological mechanisms behind the anti-respiratory depressant effects of CX-717, and demonstrated {{that it can be}} used in humans alongside opioid drugs to reduce this side effect without affecting analgesia.|$|E
5000|$|While the {{carbamate}} acetylcholinesterase inhibitors {{are commonly}} referred to as [...] "carbamate insecticides" [...] due to their generally high selectivity for insect acetylcholinesterase enzymes over the mammalian versions, the most potent compounds such as aldicarb and carbofuran are still capable of inhibiting mammalian acetylcholinesterase enzymes at low enough concentrations that they pose a significant risk of poisoning to humans, especially when used in large amounts for agricultural applications. Other carbamate based acetylcholinesterase inhibitors are known with even higher toxicity to humans, and some such as T-1123 and EA-3990 were investigated for potential military use as nerve agents. However, since all compounds of this type have a quaternary ammonium group with a permanent positive charge, they have poor <b>blood-brain</b> <b>barrier</b> <b>penetration,</b> and also are only stable as crystalline salts or aqueous solutions, and so were not considered to have suitable properties for weaponisation.|$|E
50|$|GSK2606414 {{is a drug}} {{which is}} the first {{selective}} inhibitor discovered for the enzyme protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), which is involved in various processes relating to cancer and neurodegenerative disorders. GSK2606414 was found to be a potent and selective inhibitor of PERK, with good oral bioavailability and <b>blood-brain</b> <b>barrier</b> <b>penetration.</b> PERK mediates the unfolded protein response pathway which is involved in the initiation of protein synthesis, and this pathway has been implicated in the neurotoxicity of various diseases including prion and Alzheimer's diseases. Treatment with GSK2606414 was found to be neuroprotective in mice against damage caused by prions, and prevented the development of cognitive deficits and other clinical manifestations of prion disease. Extension of lifespan in treated mice was, however, not recorded. However, side effects such as weight loss and elevated blood glucose levels were also observed, likely due to unwanted inhibition of PERK in the pancreas gland, where it is involved in regulating insulin production.|$|E
40|$|Objectives: To {{investigate}} intact <b>blood–brain</b> <b>barrier</b> (BBB) <b>penetration</b> by doripenem and characterize doripen-em pharmacokinetics in CSF using a pharmacokinetic model. Patients and methods: Thirty-eight neurological {{patients with}} no active neurological disease or CNS infection received a single 500 mg doripenem dose before pump implantation surgery, or lumbar puncture, for intra-thecal baclofen administration. In most cases single CSF and blood {{samples were collected}} per patient and analysed for doripenem with HPLC. A two-stage pharmacokinetic analysis was performed to estimate: (i) em-pirical Bayesian estimates (EBEs) of individual doripenem plasma pharmacokinetic parameters, using plasma doripenem concentrations and literature population priors for a two-compartment model; and (ii) doripenem CSF pharmacokinetic parameters using simulated plasma concentrations from stage (i) as a forcing function. The mean values of the structural model parameters, kCSF (distribution rate constant) and PC (CSF/plasma par-tition coefficient), and the residual variability were estimated. Results: The mean estimates of the parameters were kCSF 0. 105 h 21 and PC 0. 053, corresponding to mean steady-state doripenem CSF concentrations of 0. 20 mg/L and 0. 40 mg/L for regimens of 3 × 500 mg daily and 3 × 1000 mg daily, respectively, and a mean equilibrium half-life of 6. 6 h. The model was validated internall...|$|R
40|$|Partly due to poor <b>blood–brain</b> <b>barrier</b> drug <b>penetration</b> the {{treatment}} options for many brain diseases are limited. To safely enhance drug delivery to the brain, glutathione PEGylated liposomes (G-Technology) were developed. In this study, in rats, {{we compared the}} pharmacokinetics and organ distribution of GSH-PEG liposomes using an autoquenched fluorescent tracer after intraperitoneal administration and intravenous administration. Although the appearance of liposomes in the circulation was much slower after intraperitoneal administration, comparable maximum levels of long circulating liposomes were found between 4 and 24 h after injection. Furthermore, 24 h after injection a similar tissue distribution was found. To investigate the effect of GSH coating on brain delivery in vitro uptake studies in rat brain endothelial cells (RBE 4) and an in vivo brain microdialysis study in rats were used. Significantly more fluorescent tracer was found in RBE 4 cell homogenates incubated with GSH-PEG liposomes compared to non-targeted PEG liposomes (1. 8 -fold, p 50. 001). In the microdialysis study 4 -fold higher (p 50. 001) brain levels of fluorescent tracer were found after intravenous injection of GSH-PEG liposomes compared with PEG control liposomes. The results support further investigation into the versatility of GSH-PEG liposomes for enhanced drug delivery to the brain within a tolerable therapeutic window...|$|R
40|$|The fungal {{pathogen}} Cryptococcus neoformans is {{a leading}} cause of illness and death in persons with predisposing factors, including: malignancies, solid organ transplants, and corticosteroid use. C. neoformans is ubiquitous in the environment and enters into the lungs via inhalation, where it can disseminate through the bloodstream and penetrate the central nervous system (CNS), resulting in a difficult to treat and often-fatal infection of the brain, called meningoencephalitis. Plasminogen is a highly abundant protein found in the plasma component of blood and is necessary for the degradation of fibrin, collagen, and other structural components of tissues. This fibrinolytic system is utilized by cancer cells during metastasis and several pathogenic species of bacteria have been found to manipulate the host plasminogen system to facilitate invasion of tissues during infection by modifying the activation of this process through the binding of plasminogen at their surface. The invasion of the brain and the central nervous system by penetration of the protective <b>blood-brain</b> <b>barrier</b> is a prerequisite to the establishment of meningoencephalitis by the opportunistic fungal pathogen C. neoformans. In this study, we examined the ability of C. neoformans to subvert the host plasminogen system to facilitate tissue barrier invasion. Through a combination of biochemical, cell biology, and proteomic approaches, we have shown that C. neoformans utilizes the host plasminogen system to cross tissue barriers, providing support for the hypothesis that plasminogen-binding may contribute to the invasion of the <b>blood-brain</b> <b>barrier</b> by <b>penetration</b> of the brain endothelial cells and underlying matrix. In addition, we have identified the cell wall-associated proteins that serve as plasminogen receptors and characterized both the plasminogen-binding and plasmin-activation potential for this significant human pathogen. The results of this study provide evidence for the cooperative role of multiple virulence determinants in C. neoformans pathogenesis and suggest new avenues for the development of anti-infective agents in the prevention of fungal tissue invasion...|$|R
5000|$|... 2′-Acetoxycocaine (ortho-acetoxy-cocaine) is a cocaine analog, with {{a quicker}} effect onset than cocaine. The acetoxy branch renders the {{molecule}} a QSAR of a 4-fold increase over cocaine in its binding potency for the dopamine transporter & a 35-fold enhanced {{affinity for the}} norepinephrine transporter. It also has a reduced selectivity for the serotonin transporter (though only due to its greater increase at NET & DAT binding being of such {{an order of magnitude}} more by comparison). In overall binding affinity (not uptake inhibition) it displaces ligands better across the board than cocaine in all monoamine categories. Salicylmethylecgonine would be an intermediate metabolite in vivo in humans (therefore affecting the overall effect profile of the administered 2′-acetoxy analog via its metabolic route; giving it nearly three times the affinity for DAT, after onset, and greaten the affinity that is would have for NET by a halve more than on upon initial exposure, after rapid deacetylation.) 2′-Acetoxycocaine has a closer to optimum LogP (a square value of 2) for <b>blood-brain</b> <b>barrier</b> <b>penetration</b> (cocaine being higher and logarithmically four times the optimal lipophilicity allowing too much of the compound to be dumped out directly into fatty tissue instead of reaching its target site) this would make it a prodrug to salicylmethylecgonine due to the latter having a less (and the ortho-acetoxy analog having a more) efficacious LogP than its cocaine parent.|$|E
3000|$|... i to human, rat {{and mouse}} P 2 X 7 receptors. In vivo, [18 F]EFB {{displayed}} a desirable distribution profile, {{and while it}} showed low <b>blood–brain</b> <b>barrier</b> <b>penetration,</b> brain uptake was quantifiable and displayed significantly higher mean longitudinal uptake in inflamed versus control rat CNS regions.|$|E
40|$|Motivation. It is {{important}} {{to determine whether a}} candidate molecule is capable of penetrating the blood-brain barrier in drug discovery and development. The aim {{of this paper is to}} establish a predictive model for <b>blood-brain</b> <b>barrier</b> <b>penetration</b> only using two simple descriptors, molecular volume and polar surface area. Method. A dataset of 111 compounds is divided into a training set of 86 compounds and a test set of 25 compounds. Molecular volumes and polar surface areas are obtained from the molecular conformations optimized using the semiempirical self-consistent field molecular orbital calculation AM 1 method. The model to predict <b>blood-brain</b> <b>barrier</b> <b>penetration</b> from molecular volume and polar surface area is derived on the training set using the stepwise multiple regression analysis and then cross-validated using leave-one-out procedure and tested on the external prediction. Results. The logarithm of the ratio of the steady-state concentration of a compound in the brain to in the blood, logBB, is correlated with its molecular volume parabolically and its polar surface area inversely. Both calculated logBB values for the training set and predicted logBB values for the test set are in good agreement with respective experimental ones. Conclu*sions. The model derived in this paper appears to be very simple but robust and effective for predictive use, so it is suitable for the rapid prediction of the <b>blood-brain</b> <b>barrier</b> <b>penetration</b> for a wide range of drug candidates...|$|E
40|$|FLZ, a novel anti-Parkinson’s disease (PD) {{candidate}} drug, {{has shown}} poor <b>blood-brain</b> <b>barrier</b> (BBB) <b>penetration</b> {{based on the}} pharmacokinetic study using rat brain. P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are two important transporters obstructing substrates entry into the CNS {{as well as in}} relation to PD neuropathology. However, it is unclear whether P-gp and BCRP are involved in low BBB permeability of FLZ and what the differences of FLZ brain penetration are between normal and Parkinson’s conditions. For this purpose, in vitro BBB models mimicking physiological and PD pathological-related BBB properties were constructed by C 6 astroglial cells co-cultured with primary normal or PD rat cerebral microvessel endothelial cells (rCMECs) and in vitro permeability experiments of FLZ were carried out. High transepithelial electrical resistance (TEER) and low permeability for sodium fluorescein (NaF) confirmed the BBB functionality of the two models. Significantly greater expressions of P-gp and BCRP were detected in PD rCMECs associated with the lower in vitro BBB permeability of FLZ in pathological BBB model compared with physiological model. In transport studies only P-gp blocker effectively inhibited the efflux of FLZ, which was consistent with the in vivo permeability data. This result was also confirmed by ATPase assays, suggesting FLZ is a substrate for P-gp but not BCRP. The present study first established in vitro BBB models reproducing PD-related changes of BBB functions in vivo and demonstrated that poor brai...|$|R
40|$|This work {{summarizes}} {{relevant information}} about bacterial ecosystem of human intestine {{with an emphasis}} on microbiome-host communication. I describe physiological mechanisms influencing so as distant as the intestine and the brain. Neuropsychiatrical and neurodevelopmental disorders, especially autism, are used as a model. Human gut microbiome influences function and development of the brain in many ways. The intestinal barrier permeability increases and decreases by the consequences of microbes contact with epithelium. Many bacterial species produce neuroactive molecules, neurotransmiters, their precursors and fatty acids. These molecules enter the bloodstream depending on intestinal barrier tightness. Disruption of microecosystem and host communication may cause pathological inflammations and increase cytokine production. Cytokines are able to weaken the <b>blood-brain</b> <b>barrier</b> and enable <b>penetration</b> of potentially harmful substances into the brain. The main goal of this bachelor thesis is to summarize and logically organise current information and point out important questions about the relations between the microbiome composition and mental health. In conclusion, bacterial microbiome influences brain functions in health and disease. Ecological destabilisation of microbiome is one of the factors [...] ...|$|R
40|$|Background: We have {{explored}} {{the possibility that}} the serotonin 1 B receptor radioligand [C- 11]AZ 10419369 is a substrate for adenosine triphosphate (ATP) -binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), Mrp 4, and Bcrp, in rodents and whether there is a species difference regarding its <b>blood-brain</b> <b>barrier</b> (BBB) <b>penetration.</b> Methods: In a series of preclinical positron emission tomography measurements, we have administered [C- 11]AZ 10419369 to mice, rats, and guinea pigs under baseline conditions and, on separate experimental days, after administration of the ABC transporter inhibitor, cyclosporin A (CsA). Results: During baseline conditions, the brain uptake was low in mice and rats, but not in guinea pigs. After CsA pretreatment, the peak whole brain uptake values of [C- 11]AZ 10419369 increased by 207 % in mice, 94 % in rats, and 157 % in guinea pigs. Binding potentials (BPND) could not be estimated during baseline conditions in mice and rats. After CsA pretreatment, the highest BPND values were obtained in the striatum and thalamus (BPND approximate to 0. 4) in mice, while in rats, the highest binding areas were the striatum, thalamus, hypothalamus, and periaqueductal gray (BPND approximate to 0. 5). In guinea pigs, we did not find any significant changes in BPND between baseline and CsA pretreatment, except in the striatum. Conclusions: The results indicate that BBB penetration of [C- 11]AZ 10419369 was hindered by ABC transporter activity in mouse, rat, and guinea pig. This study highlights the importance of ABC transporters in the design of preclinical positron emission tomography (PET) studies...|$|R
